- Home
- WFF vs ATOS Comparison
WFF vs ATOS Comparison
Compare WFF & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFF | ATOS |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 24.1M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | WFF | ATOS |
|---|---|---|
| Price | $2.01 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 6.5M | 57.2K |
| Earning Date | 05-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.53 |
| 52 Week High | $10.71 | $7.56 |
Technical Indicators
Market Signals| Indicator | WFF | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 48.09 |
| Support Level | $1.94 | $2.05 |
| Resistance Level | $2.46 | $2.60 |
| Average True Range (ATR) | 0.92 | 0.17 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 6.55 | 26.50 |
Price Performance
Historical ComparisonAbout WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings, and other custom-made FRP products. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance. Geographically, the company generates the majority of its revenue from Australia.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.